Aurigene Pharmaceutical Services, a Dr Reddy’s Laboratories unit, has officially opened a new biologics facility at Genome Valley in the Indian city of Hyderabad.

The 70,000ft² facility is equipped to provide process and analytical development, as well as small-scale manufacturing of antibodies and other recombinant proteins for preclinical and early-phase clinical trials.

The process and analytical development laboratories at the facility are already operational and the manufacturing capacity is expected to be commissioned later in 2024.

The facility features robust equipment and control systems and is supported by a skilled workforce to ensure a smooth transition to large-scale commercial current good manufacturing practice operations.

The new facility complements Aurigene’s existing discovery capabilities and infrastructure, which focus on a range of recombinant proteins.

These proteins include monoclonal antibodies, bi and multi-specifics, immune-fusion molecules, antibody-drug conjugates and other complex proteins.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

With the opening of the Hyderabad facility, Aurigene is equipped to offer comprehensive end-to-end services, from discovery through to large-scale commercial manufacturing, across three closely situated campuses.

The facility will also provide compliant and economically viable cell lines, along with process development solutions and analytical methods.

These services are aimed at customers looking to advance rapidly through the stages of clinical development.

The launch of the facility is part of Aurigene’s strategic initiatives to support growth in both the small molecule and biologics sectors.

Aurigene CEO Akhil Ravi stated: “The journey started a year back when we decided to invest in creating the facility. It is great to see the facility operational and the addition of this capacity and capabilities shows our firm commitment to the continued expansion of our biologics business, building on 25 years of proven experience.

“The state-of-the-art facility will enable us to service our global customers efficiently and support the development of innovative medicine.”